AbbVie to develop Lupin’s cancer drug
Lupin Ltd. on Monday announced a partnership with global pharmaceutical giant AbbVie for the development and commercialisation of its novel oncology drug to treat hematological cancers. AbbVie has entered into a licensing agreement with Lupin for its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor programme and taken the responsibility for further development and launch of the drug in the market. Through this partnership, AbbVie has gained exclusive global rights to develop and commercialise Lupin’s MALT1 inhibitors. Under the terms of the agreement, AbbVie would give Lupin an upfront payment of $30 million for an exclusive licence to the programme. Upon successful completion of regulatory, development and commercial milestones, Lupin is eligible to receive total milestone payments of up to $947 million. Double-digit royalty Additionally, Lupin will be entitled to receive a double-digit royalty on sales of the product and r...